Who is sponsoring NCT06220435?

NCT06220435 is sponsored by Region Skane.

What drugs are being tested in NCT06220435?

Interventions in NCT06220435: Ultra-hypofractionated radiotherapy regimen..

What condition does NCT06220435 study?

NCT06220435 studies Prostate Cancer.

Is NCT06220435 still recruiting?

NCT06220435 is currently recruiting now. Last updated 12 August 2025.

Last reviewed 2025-08-12 · How we verify

NCT06220435

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer

Recruiting now NA Last updated 12 August 2025

What this trial tests

NA trial testing Ultra-hypofractionated radiotherapy regimen. in Prostate Cancer in 76 participants. Currently enrolling.

Timeline

25 September 2023

Primary endpoint
1 September 2031

1 September 2031

Quick facts

Lead sponsor	Region Skane
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	76
Start date	25 September 2023
Primary completion	1 September 2031
Estimated completion	1 September 2031
Sites	2 locations across Sweden

Drugs / interventions tested

Ultra-hypofractionated radiotherapy regimen.

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Region Skane — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HYPO-RT-PC boost is is an open-label, multicentre, phase II trial evaluating safety and efficacy of real-time image-guided tumor-directed ultra-hypofractionated radiation boost and lymph node irradiation for patients with node-negative high risk localized prostate cancer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ultra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological reference.
Nilsson E, Nilsson A, Jonsson J, Sandgren K, et al · · 2025 · PMID 41146436 · DOI 10.2340/1651-226x.2025.44211

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Region Skane trials

Trials by the same sponsor.

NCT07511673 — The Study is a Randomised Clinical Trial (RCT) to Test if Preoperative Dental Screening is Superior to no Preoperative D · NA · not yet recruiting
NCT07169747 — Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young · Phase 2 · recruiting
NCT07494669 — Proteomics and Physiological Parameters Predicting Complications After Colorectal Cancer Surgery · not yet recruiting
NCT07462351 — System-integrated Point-of-Care Ultrasound in Breast Cancer Screening · NA · recruiting
NCT06975696 — Fusion Imaging in Endovascular Thrombectomy for Acute Ischemic Stroke · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06220435 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Region Skane
Last refreshed: 12 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06220435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing